×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HRTX – heron therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HRTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
08:15 am
hrtx
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
Medium
Report
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
11/6
05:10 pm
hrtx
Heron Therapeutics: Stagnant Cash Cow, Blockbuster That Wasn't - Steer Clear [Seeking Alpha]
Neutral
Report
Heron Therapeutics: Stagnant Cash Cow, Blockbuster That Wasn't - Steer Clear [Seeking Alpha]
11/4
08:12 pm
hrtx
Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Medium
Report
Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
11/4
08:00 am
hrtx
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
Medium
Report
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
10/29
05:58 pm
hrtx
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
Low
Report
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
10/21
04:20 pm
hrtx
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Medium
Report
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
10/9
07:15 am
hrtx
Heron Therapeutics (NASDAQ:HRTX) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Heron Therapeutics (NASDAQ:HRTX) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
9/9
05:30 pm
hrtx
Heron Therapeutics files $125M mixed securities shelf [Seeking Alpha]
Medium
Report
Heron Therapeutics files $125M mixed securities shelf [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/26
10:16 am
hrtx
Form SCHEDULE 13G HERON THERAPEUTICS, INC. Filed by: Clearline Capital LP
Low
Report
Form SCHEDULE 13G HERON THERAPEUTICS, INC. Filed by: Clearline Capital LP
11/12
09:20 am
hrtx
Form 4 HERON THERAPEUTICS, INC. For: Nov 08 Filed by: Cusack Thomas
Medium
Report
Form 4 HERON THERAPEUTICS, INC. For: Nov 08 Filed by: Cusack Thomas
11/7
09:31 am
hrtx
Form 3 HERON THERAPEUTICS, INC. For: Oct 27 Filed by: Cusack Thomas
Low
Report
Form 3 HERON THERAPEUTICS, INC. For: Oct 27 Filed by: Cusack Thomas
11/4
12:35 pm
hrtx
Form 4 HERON THERAPEUTICS, INC. For: Oct 31 Filed by: Forbes William P
Low
Report
Form 4 HERON THERAPEUTICS, INC. For: Oct 31 Filed by: Forbes William P
11/4
12:34 pm
hrtx
Form 4 HERON THERAPEUTICS, INC. For: Oct 31 Filed by: Duarte Ira
Low
Report
Form 4 HERON THERAPEUTICS, INC. For: Oct 31 Filed by: Duarte Ira
11/4
12:31 pm
hrtx
Form 4 HERON THERAPEUTICS, INC. For: Oct 31 Filed by: Collard Craig A
Low
Report
Form 4 HERON THERAPEUTICS, INC. For: Oct 31 Filed by: Collard Craig A
11/4
08:01 am
hrtx
Form 10-Q HERON THERAPEUTICS, INC. For: Sep 30
Medium
Report
Form 10-Q HERON THERAPEUTICS, INC. For: Sep 30
11/4
08:00 am
hrtx
Form 8-K HERON THERAPEUTICS, INC. For: Nov 04
Medium
Report
Form 8-K HERON THERAPEUTICS, INC. For: Nov 04
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/9
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress
10.1%
10/28 Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain 9.0%
10/1 Heron Therapeutics Inc (NASDAQ: HRTX) had its "outperform" rating re-affirmed by analysts at JMP Securities. They now have a $38.00 price target on the stock, up previously from $33.00. 6.6%
2/19 Form 8-K HERON THERAPEUTICS, INC. For: Feb 18 5.8%
1/13 Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises 5.8%
10/3 Heron Therapeutics Inc (NASDAQ: HRTX) had its price target lowered by analysts at JMP Securities to $32.00. They now have a "positive" rating on the stock. 5.2%
10/4 Heron Therapeutics (HRTX) Investor Presentation - Slideshow [Seeking Alpha] 4.7%
4/17 Form 4 HERON THERAPEUTICS, INC. For: Apr 15 Filed by: Christian Waage 4.6%
11/15 Heron Therapeutics: Looking Solid Heading Into 2020 [Seeking Alpha] 3.9%
11/13 Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference 3.6%
10/28 Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain 9.0%
10/1 Heron Therapeutics Inc (NASDAQ: HRTX) had its "outperform" rating re-affirmed by analysts at JMP Securities. They now have a $38.00 price target on the stock, up previously from $33.00. 6.6%
2/19 Form 8-K HERON THERAPEUTICS, INC. For: Feb 18 5.8%
1/13 Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises 5.8%
10/3 Heron Therapeutics Inc (NASDAQ: HRTX) had its price target lowered by analysts at JMP Securities to $32.00. They now have a "positive" rating on the stock. 5.2%
10/4 Heron Therapeutics (HRTX) Investor Presentation - Slideshow [Seeking Alpha] 4.7%
4/17 Form 4 HERON THERAPEUTICS, INC. For: Apr 15 Filed by: Christian Waage 4.6%
11/15 Heron Therapeutics: Looking Solid Heading Into 2020 [Seeking Alpha] 3.9%
11/13 Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference 3.6%
TOP News Decliners
4/30
Heron Therapeutics Inc (NASDAQ: HRTX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
-13.0%
10/3 Heron Therapeutics Announces Proposed Public Offering of Common Stock -8.8%
10/1 Heron Therapeutics Inc (NASDAQ: HRTX) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $40.00 price target on the stock. -6.9%
10/22 Form 8-K HERON THERAPEUTICS, INC. For: Oct 22 -5.9%
1/13 Form 8-K HERON THERAPEUTICS, INC. For: Jan 13 -5.5%
5/22 Heron Therapeutics Inc (NASDAQ: HRTX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -4.7%
3/5 Heron Therapeutics (HRTX) Presents At SVB Leerink Global Healthcare Conference - Slideshow [Seeking Alpha] -4.5%
11/13 Heron Therapeutics Inc (NASDAQ: HRTX) had its "buy" rating re-affirmed by analysts at Northland Securities. They now have a $47.00 price target on the stock. -4.2%
4/9 Heron Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference -3.7%
2/25 Heron Therapeutics to Present at the 40th Annual Cowen Healthcare Conference -3.6%
10/3 Heron Therapeutics Announces Proposed Public Offering of Common Stock -8.8%
10/1 Heron Therapeutics Inc (NASDAQ: HRTX) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $40.00 price target on the stock. -6.9%
10/22 Form 8-K HERON THERAPEUTICS, INC. For: Oct 22 -5.9%
1/13 Form 8-K HERON THERAPEUTICS, INC. For: Jan 13 -5.5%
5/22 Heron Therapeutics Inc (NASDAQ: HRTX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -4.7%
3/5 Heron Therapeutics (HRTX) Presents At SVB Leerink Global Healthcare Conference - Slideshow [Seeking Alpha] -4.5%
11/13 Heron Therapeutics Inc (NASDAQ: HRTX) had its "buy" rating re-affirmed by analysts at Northland Securities. They now have a $47.00 price target on the stock. -4.2%
4/9 Heron Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference -3.7%
2/25 Heron Therapeutics to Present at the 40th Annual Cowen Healthcare Conference -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: